<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586050</url>
  </required_header>
  <id_info>
    <org_study_id>NEU_2017_01</org_study_id>
    <nct_id>NCT03586050</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea</brief_title>
  <official_title>A Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, non-randomized, single center study to evaluate ablation, oncologic&#xD;
      outcomes and safety in the treatment of hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single-arm single center study will provide clinical data for the Neuwave&#xD;
      Medical Microwave Ablation System and accessories.&#xD;
&#xD;
      Individuals who undergo microwave ablation of liver tumors who meet study entry criteria,&#xD;
      will be enrolled.&#xD;
&#xD;
      The enrollment for the study will continue until 30 eligible subjects complete the 3-month&#xD;
      visit after ablation for the primary effectiveness and safety analysis.&#xD;
&#xD;
      The subjects will be followed for approximately up to 36 months after the ablation procedure&#xD;
      for safety, oncologic and ablation outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">May 21, 2023</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Whose Ablation Resulted in Technical Success</measure>
    <time_frame>immediately following (or up to 4 days after) the ablation procedure (Day 0)</time_frame>
    <description>complete tumor ablation with adequate or insufficient margin, based on contrast-enhanced MRI and CT scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Whose Ablation Resulted in Technique Efficacy</measure>
    <time_frame>1 month after the ablation procedure (Day 0)</time_frame>
    <description>complete tumor ablation with adequate or insufficient ablation margin based on contrast-enhanced MRI and CT scans; scans may be done up to 14 days prior to the 1 month visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatocellular Cancer</condition>
  <condition>Cancer, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Microwave Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave ablation</intervention_name>
    <description>All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories</description>
    <arm_group_label>Microwave Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed hepatocellular carcinoma, tumor size of more than 2 cm and up to 5cm, single&#xD;
             location, Barcelona Clinic Liver Cancer (BCLC) Stage A based on imaging and biopsy&#xD;
             confirmation&#xD;
&#xD;
          2. Primary hepatocellular carcinoma or recurrent hepatocellular carcinoma which was&#xD;
             previously treated with ablation or surgical resection only;&#xD;
&#xD;
          3. Scheduled for microwave ablation of the liver;&#xD;
&#xD;
          4. Performance status 0-1 (Eastern Cooperative Oncology Group classification);&#xD;
&#xD;
          5. Functional hepatic reserve based on the Child-Pugh score (Class A or B);&#xD;
&#xD;
          6. American Society of Anesthesiologists (ASA) score &lt; 3;&#xD;
&#xD;
          7. Given voluntary, written informed consent to participate in this study and has&#xD;
             authorized the transfer of his/her information to the Sponsor, and willing to comply&#xD;
             with study-related evaluation and treatment schedule;&#xD;
&#xD;
          8. At least 19 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active bacterial infection or fungal infection;&#xD;
&#xD;
          2. Systemic administration of steroids, including herbal supplements that contain&#xD;
             steroids, within 30 days prior to the study procedure;&#xD;
&#xD;
          3. Chemotherapy or radiation therapy for hepatocellular carcinoma may not be performed&#xD;
             for 30 days prior to the study procedure;&#xD;
&#xD;
          4. Subject with implantable pacemakers or other electronic implants;&#xD;
&#xD;
          5. Planned/ scheduled liver surgery.&#xD;
&#xD;
          6. Subject with a platelet count of less than 20,000/mm3;&#xD;
&#xD;
          7. Subject with an INR greater than 1.5;&#xD;
&#xD;
          8. Subject with renal failure on renal dialysis;&#xD;
&#xD;
          9. Scheduled concurrent procedure other than microwave ablation in the liver;&#xD;
&#xD;
         10. Pregnant or lactating;&#xD;
&#xD;
         11. Physical or psychological condition which would impair study participation;&#xD;
&#xD;
         12. Participation in any other clinical study concurrently or within the last 3 months;&#xD;
&#xD;
         13. The subject is judged unsuitable for study participation by the Investigator for any&#xD;
             other reason;&#xD;
&#xD;
         14. Unable or unwilling to attend follow-up visits and examinations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyunchul Rhim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <results_first_submitted>May 3, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma; liver cancer; cancer; liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03586050/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from 04Dec2017 through 21May2020</recruitment_details>
      <pre_assignment_details>Enrollment for the study continued until 30 subjects, who were treated per protocol, completed the 3-month visit after the ablation visit (Day 0) for the primary effectiveness and safety analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Microwave Ablation</title>
          <description>Each participant underwent microwave ablation of a liver tumor (Hepatocellular Carcinoma (HCC)) at a single visit. The treating physician determined the ablation time and power used on a case-by-case basis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>33 total patients were enrolled, to allow for 30 patients to be treated per protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Microwave Ablation</title>
          <description>Each participant underwent microwave ablation of a liver tumor (Hepatocellular Carcinoma (HCC)) at a single visit. The treating physician determined the ablation time and power used on a case-by-case basis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age of patient at the time of informed consent</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Tumor Dimension</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.49" spread="0.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver Segment</title>
          <description>Location of the tumor in the liver (multiple could be selected)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Segment 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Depth</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Superficial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Major Vessel/Duct Assessment</title>
          <description>Location of the tumor/ablation in relation to a major vessel/duct</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Near Major Vessel/Duct</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Major Vessel/Duct Near Ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BCLC Staging</title>
          <description>All participants were confirmed to have BCLC staging of Stage A within 5 weeks prior to the day of ablation based on imaging and biopsy confirmation in accordance with their institution SOC. The BCLC (Barcelona Clinic Liver Cancer) staging system is validated and widely accepted as it offers the most prognostic information (i.e. includes information on tumor size/burden, liver function, and patient ECOG performance status). BCLC stages include 0, A, B, C and D.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0 (Very early stage disease; Child-Pugh score of A, ECOG 0-1, single tumor &lt; 2cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (Early stage disease; Child-Pugh score of A/B, ECOG 0-1, single or 2-3 tumors &lt; 3cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Intermediate stage disease; Child-Pugh score of A/B, ECOG 0-1, multinodular tumors)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C (Advanced stage disease; Child-Pugh score of A/B, ECOG 0-2, portal vein invasion)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D (Terminal disease; Child-Pugh score C, ECOG&gt;2, metastasized tumors to lymph nodes or other organs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh Score</title>
          <description>All participants were confirmed to have functional hepatic reserve based on the Child-Pugh score (Class A or Class B) within 5 weeks prior to the day of ablation. Child-Pugh Scores assess the prognosis of liver disease. Five clinical features are assessed and assigned 1-3 points depending on severity (1 being none, 2 being mild, and 3 being severe): encephalopathy, presence of ascites, bilirubin blood level, albumin blood level, and prothrombin time prolongation. Classes A, B, and C are based on the total number of points.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Class A (mild liver disease; 5-6 points)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B (moderately severe liver disease; 7-9 points)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class C (severe liver disease; 10-15 points)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Whose Ablation Resulted in Technical Success</title>
        <description>complete tumor ablation with adequate or insufficient margin, based on contrast-enhanced MRI and CT scans</description>
        <time_frame>immediately following (or up to 4 days after) the ablation procedure (Day 0)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Microwave Ablation</title>
            <description>Each participant underwent microwave ablation of a liver tumor (Hepatocellular Carcinoma (HCC)) at a single visit. The treating physician determined the ablation time and power used on a case-by-case basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Whose Ablation Resulted in Technical Success</title>
          <description>complete tumor ablation with adequate or insufficient margin, based on contrast-enhanced MRI and CT scans</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PI Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Independent Reviewer Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Whose Ablation Resulted in Technique Efficacy</title>
        <description>complete tumor ablation with adequate or insufficient ablation margin based on contrast-enhanced MRI and CT scans; scans may be done up to 14 days prior to the 1 month visit</description>
        <time_frame>1 month after the ablation procedure (Day 0)</time_frame>
        <population>Participants analyzed at 1 month post-ablation</population>
        <group_list>
          <group group_id="O1">
            <title>Microwave Ablation</title>
            <description>Each participant underwent microwave ablation of a liver tumor (Hepatocellular Carcinoma (HCC)) at a single visit. The treating physician determined the ablation time and power used on a case-by-case basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Whose Ablation Resulted in Technique Efficacy</title>
          <description>complete tumor ablation with adequate or insufficient ablation margin based on contrast-enhanced MRI and CT scans; scans may be done up to 14 days prior to the 1 month visit</description>
          <population>Participants analyzed at 1 month post-ablation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PI Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Independent Reviewer Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were assessed for safety from the day of the ablation (Day 0) through the 3-month visit (+/- 28 days).</time_frame>
      <desc>Participants will be evaluated for AEs and SAEs at every study visit starting with the ablation procedure (Day 0) through the end-of-study (3 years following the ablation procedure). Adverse event data collection is still ongoing and will be updated upon study completion.</desc>
      <group_list>
        <group group_id="E1">
          <title>Microwave Ablation</title>
          <description>Each participant underwent microwave ablation of a liver tumor (Hepatocellular Carcinoma (HCC)) at a single visit. The treating physician determined the ablation time and power used on a case-by-case basis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA pref. term</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA pref. term</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaclyn Calia</name_or_title>
      <organization>ETHICON</organization>
      <phone>908-218-2933</phone>
      <email>jcalia@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

